Arkolith/Insider Trading/XENE/Form 4

Mortimer Ian

PRESIDENT, CEO & INTERIM CFO, DirectorXenon Pharmaceuticals Inc. (XENE) · full profile →Form 4 · filed Oct 1, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.0M
Net Open-Market Flow
-$1.0M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 1, 2025Sell(S)25K$40.16$1.0M31K
Oct 1, 2025Option exercise(M)25K$7.69$192K56K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 1, 2025Option exercise(M)25K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-227202) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML